Expensify Inc (EXFY) Stock Price Today
NVIDIA Board launches probe into CEO Jensen Huang over foreign intelligence concerns.
NVIDIA's Board of Directors has started an independent investigation after reports that CEO Jensen Huang was targeted by a foreign intelligence operation. The inquiry, led by independent directors and external counsel, aims to ensure no national secu...
Nvidia launches probe after CEO Jensen Huang linked to Chinese spy allegations.
Nvidia's board announced an independent investigation after reports surfaced that CEO Jensen Huang was targeted by a Chinese spy operation through an affair with Alice Huang, a former chip executive allegedly recruited by Chinese intelligence. Jensen...
South Korean stocks plunge over 8% on Friday amid tech turmoil and AI regulation fears
South Korea's Kospi index dropped more than 8% on Friday, reflecting global tech sector instability and concerns about stricter AI regulations under Democratic governments. This sharp decline signals heightened market volatility and investor caution,...
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.
CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...
Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.
Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...
AVITA Medical to host investor webinar on Nov 11 covering Q3 2026 results and business update
AVITA Medical announced an investor webinar on November 11, 2026, where CEO Cary Vance and CFO David O’Toole will discuss the company's third-quarter 2026 financial and business results. The session will include a Q&A segment for participants who can...
Reinvesting dividends turned $1,000 in Procter & Gamble into $4,656 over 20 years.
Investing $1,000 in Procter & Gamble (P&G) in 2006 and reinvesting all dividends grew the investment to $4,656 by 2026. P&G's steady demand for everyday products supports 70 consecutive years of dividend increases, with dividends rising from $0.31 to...
3 stocks with recurring revenue face challenges but offer long-term growth potential.
Three companies—Otis Worldwide, Rollins, and Republic Services—offer recurring revenue through essential services like elevator maintenance, pest control, and waste management. Despite their steady cash flows and customer loyalty, Otis and Rollins fa...
Lawsuit probes J.B. Hunt for allegedly misleading investors after Q3 earnings warning
Rosen Law Firm is investigating J.B. Hunt Transport Services for possibly providing misleading business information to investors after the company warned of a Q3 earnings decline. The firm's shares dropped sharply following a CNBC report about increa...
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.
Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.